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1. Abstract 
1.1. Aims: 
 Sleep disordered breathing (SDB) may contribute to disease progression in patients with 
chronic heart failure (CHF). The objective of this observational study was to evaluate whether 
SDB is a risk factor for mortality in CHF patients and whether this risk can be attenuated by 
treatment with positive airway pressure (PAP). 
 
1.2. Methods and results: 
We studied 296 CHF patients (median left ventricular ejection fraction 33%) who underwent 
in-lab polysomnography between January 2002 and December 2009. We compared (i) 
mortality between patients with severe SDB [apnoea–hypopnoea index (AHI) ≥ 22.5 h-1] vs. 
those without severe SDB (AHI < 22.5 h-1) and (ii) evaluated the impact of PAP treatment on 
mortality in those with severe SDB. After accounting for significant confounding factors (age, 
NYHA class, cause of CHF, diabetes, and PAP treatment), patients with severe SDB (n = 
176) had a 2.0-fold increased hazard ratio for death compared with those without severe 
SDB [95% confidence interval (CI) 1.1–3.5, P = 0.023]. In an adjusted on-treatment analysis 
of the group with severe SDB, mortality was significantly less in patients using PAP (18%) 
compared with those with untreated SDB (52%; hazard ratio 0.4, 95% CI 0.2–0.6, P = 0.001). 
Mortality in the PAP-treated group was lower compared with the untreated group at any time-
point of the follow-up period. 
 
1.3. Conclusion: 
The presence of severe SDB in CHF patients constitutes a significantly increased risk for 
death, independent of established risk factors. In CHF patients with SDB, use of PAP therapy 
was associated with a decreased mortality rate at any time point of the follow-up, suggesting 
that PAP can be safely used in such patients. 
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2. Introduction 
Sleep disordered breathing (SDB) is highly prevalent (51–71%) among patients with chronic 
heart failure (CHF).1 – 4 By exposing the failing heart to intermittent hypoxia, increased 
preload and afterload,5 sympathetic nervous system activation,6 and vascular endothelial 
dysfunction, SDB may promote disease progression.7 The main clinical significance of SDB 
in CHF is its potential to contribute to mortality.7 However, published data evaluating the 
impact of SDB on mortality in CHF patients are controversial. Some studies suggest that 
SDB is an independent predictor of mortality in this patient group.8 – 13 In contrast to those 
findings, Andreas et al. and Roebuck et al. did not observe a significantly increased mortality 
rate in CHF patients with SDB compared with those without.14, 15 Yumino et al.16 recently 
reported that SDB is only an independent risk factor for death in patients with ischaemic 
cardiomyopathy, and not in patients with non-ischaemic cardiomyopathy. 
In addition, the conclusions that can be drawn from the above studies are limited due to (i) 
small sample size, (ii) use of portable monitoring devices that do not allow the distinction 
between obstructive and central sleep apnoea (OSA and CSA),8,11 and (iii) unknown9,11,17 or 
limited use (10–53%)8,10,12,18 of beta-blockers, which have an impact on survival in heart 
failure patients.19,20 The results of previous studies with limited use of beta-blockers cannot 
be extrapolated to patients on contemporary optimal CHF therapy. 
The application of different forms of positive airway pressure (PAP) is an effective treatment 
of SDB in CHF patients that also improves surrogates of long-term cardiac outcome such as 
cardiac afterload, heart rate, sympathetic tone21 as well as left ventricular ejection fraction 
(LVEF).22 – 24 However, in the largest randomized trial evaluating the effects of continuous 
PAP in CHF patients with CSA on transplant-free survival, the total number of events in both 
arms of the trial (control and continuous PAP) was identical. Due to an increased early event 
rate in the continuous PAP arm, deleterious effects of PAP therapy in some CHF patients 
could not be ruled out.22 We therefore evaluated the following hypotheses in a large sample 
of CHF patients on contemporary medical therapy, who underwent full in-laboratory 
10 
 
polysomnography: (i) SDB including CSA and OSA is an independent risk factor for death in 
patients with CHF. (ii) Treatment with PAP is associated with a decreased mortality rate in 
patients with severe SDB and CHF. The in-hospital initiation of PAP therapy targeted at 
suppression of SDB is not associated with an increased early mortality rate. 
 
3. Methods 
3.1. Patients 
We studied 411 CHF patients who underwent polysomnography and objective assessment of 
LVEF within 3 months at the University Hospital Regensburg between January 2002 and 
December 2009. Inclusion criteria were: (i) objective evidence of a structural and functional 
abnormality of the heart (impaired LVEF ≤ 50%)25 and (ii) CHF due to either ischaemic, non-
ischaemic, or hypertensive cardiomyopathy.25 Exclusion criteria were (i) CHF due to valvular 
heart disease, (ii) listing for heart transplantation, (iii) severe pulmonary disease or cancer, 
as well as (iv) oxygen or PAP treatment. The study was planned according to the declaration 
of Helsinki and approved by the local ethics committee, and the subjects gave written 
informed consent.  
 
3.2. Polysomnography 
During polysomnography body position, eye and leg movements, cardiotachography, 
nasobuccal airflow, chest and abdominal effort, and arterial oxyhaemoglobin saturation 
assessed by pulse oximetry were recorded (Alice 3.5, Respironics, Pittsburgh, USA). Sleep 
stages were determined according to Rechtschaffen and Kales.26 Apnoea was defined as a 
cessation of inspiratory airflow for ≥ 10 s. Central apnoeas were those that occurred with an 
absence of thoracic and abdominal effort, while obstructive apnoeas were those that 
occurred in the presence of thoracic and abdominal motion. Hypopnoea was defined as a 
reduction in airflow of more than 50% or thoracoabdominal effort lasting at least 10 s 
resulting in a ≥ 4% drop in arterial oxyhaemoglobin saturation (SaO2). The oxygen 
desaturation index was defined as the number of ≥ 4% oxygen desaturations per hour of 
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sleep. Patients were classified as having OSA, when the predominant type of apnoea (≥ 
50%) was obstructive in nature. Central sleep apnoea was defined as < 50% obstructive 
apnoeas. 
 
3.3. Treatment 
A trial of continuous PAP treatment was offered to patients with an apnoea–hypopnoea index 
(AHI) ≥15 h-1 or AHI ≥5 h-1 plus SDB-related symptoms, e.g. excessive daytime sleepiness.27 
To acclimatize patients, continuous PAP was applied to patients at 4 cmH2O for 1 hour while 
awake. During the night, continuous PAP was started under attended polysomnographic 
control at 4 cmH2O, and was slowly increased in 1–2.5 cmH2O increments to reach the target 
pressure (usually 8–10 cmH2O) or the highest pressure the patient could tolerate (< 8 
cmH2O). Patients were sent home at the lowest CPAP level leading to optimal suppression of 
SDB and were instructed to use CPAP for at least 6 hours per night. Other forms of PAP (bi-
level PAP, 2002–2005, and adaptive servoventilation, 2005–2009) were used in patients 
whose SDB was not sufficiently suppressed by CPAP. The use of adaptive servoventilation 
in patients with an AHI >15 h-1 on continuous PAP treatment was based on a 
subanalysis of the CANPAP trial showing that continuous PAP was only associated with 
improved cardiac function and transplant-free survival, when it suppressed the AHI below 15 
h-1.28 In addition, Kohnlein et al.29 showed that continuous and bi-level PAP are equally 
effective in suppressing central respiratory events. 
 
3.4. Outcome 
The primary outcome was all-cause mortality between the day of the baseline 
polysomnography until December 2009. Physicians assessed the outcome by phone 
interview. In order to verify the causes of death of patients who died in hospital, documents 
relating to the hospital stay were evaluated. For patients with out-of-hospital death, 
documents available from the family physician were evaluated. 
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3.5. Statistical analysis 
Data distribution was assessed by the Kolmogorov–Smirnov test. Continuous data are 
expressed as means ± standard deviation, unless otherwise indicated. Student’s t-test was 
used to compare the means of groups for continuous variables, if appropriate. For 
proportions, the χ2-test with Yates’ correction was used, if necessary. A two-sided P-value < 
0.05 was considered statistically significant. In an exploratory analysis, the cut-off value of 
the AHI was calculated using the receiver operating characteristic (ROC) in regular intervals 
in order to identify the best discriminative threshold to predict outcome. The area under the 
curve was obtained according to Hanley.30 The AHI value with the maximum expression of 
the Youden index (defined as sensitivity + specificity - 1) was defined as the threshold for 
classifying patients into two groups with regard to the AHI. Kaplan–Meier estimates were 
used to visualize survival. A Cox proportional hazard model was used to compare survival 
between groups. All independent variables shown in Table 1 were introduced one at a time in 
the model. Confounding variables (Table 1 in bold) were those that conferred at least a 10% 
change in the hazard ratio for death according to the SDB category.31 Therefore, age, NYHA 
class, cause of CHF, diabetes, and PAP treatment were entered in addition to SDB category 
in the final multivariate analyses.  
To test hypothesis 1, we compared the mortality rate of the two SDB categories. To test 
hypothesis 2, we performed an intention-to-treat and an on-treatment analysis (continued 
PAP treatment for at least 6 months or until a primary event) for all patients in the severe 
SDB group. 
A propensity score was created using a logistic regression model with PAP treatment as the 
independent variable and the following covariates: age, NYHA, ischaemic cardiomyopathy as 
cause of CHF, and diabetes. The propensity score was then entered into a Cox-PH model as 
a continuous variable. All analyses were performed with the Statistical Package for the 
Social Sciences (SPSS 15.0, Chicago, IL, USA). 
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Table 1 Possible confounders for death 
 
Age, gender, body-mass index (BMI) 
LVEF, NYHA class, cause of CHF (ischaemic/non-ischaemic), Atrial fibrillation  
History of hypertension, diabetes, and hyperlipidaemia 
Biventricular pacemaker, defibrillator 
ACE-inhibitors/AT1-receptor antagonists, spironolactone, ß-receptor-blockers,  
digitalis, diuretics, lipid reducers 
Positive airway pressure treatment 
 
Significant confounders (> 10% change in hazard ratio for death according to category of sleep-
disordered breathing) are marked in bold. 
 
 
4. Results 
Four hundred and eleven patients with a diagnosis of CHF underwent polysomnography and 
evaluation of LVEF between 1 January 2002 and 31 December 2009. Two hundred and 
ninety-six patients with CHF were eligible for analysis, 115 were excluded due to either LVEF 
> 50%, listing for heart transplantation, severe lung disease, or cancer (Figure 1). 
On the basis of ROC analysis, the best cut-off value for detecting mortality was an AHI ≥ 22.5 
h-1, indicating severe SDB (n = 176). Patients with an AHI < 22.5 h-1 had absent-to-moderate 
SDB and were defined as the group without severe SDB (n = 97). The baseline 
characteristics of patients are listed in Table 2.  
The severe SDB group was significantly older, more obese, and had more severe heart 
failure, indicated by significantly higher NYHA-functional class than the group without severe 
SDB. Additionally, the proportion of men and the prevalence of diabetes and implanted 
pacemakers were significantly higher in the severe SDB group. In the group without severe 
SDB, the percentage of patients receiving spironolactone was higher than in the severe SDB 
group. 
With respect to sleep characteristics (Table 3), the severe SDB group had a higher AHI and 
arousal index as well as lower minimum oxygen saturation. The mean oxygen saturation was 
similar in both groups. Sleep efficiency and sleep time were lower in the severe SDB group 
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than in group without severe SDB. Neither sleep onset latency nor subjective sleepiness 
assessed by the Epworth Sleepiness Scale (ESS) differed significantly between groups and 
did not indicate excessive daytime sleepiness in either group (Table 3). Patients with severe 
SDB were more often PAP treated than those from the group without severe SDB (52 vs. 
22%, Table 3). 
 
 
Figure 1 Progress of the cohort through the study. CHF, chronic heart failure; PSG, polysomnography; 
mo, months; LVEF, left ventricular ejection fraction; no severe SDB, sleep-disordered breathing 
defined as apnoea–hypopnoea index < 22.5 h
-1
; severe SDB, severe sleep disordered breathing 
defined as apnoea–hypopnoea index ≥ 22.5 h
-1
. 
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Table 2 Baseline characteristics of patients without severe sleep disordered breathing 
(AHI < 22.5 h-1) and severe sleep disordered breathing (AHI ≥ 22.5 h-1) 
 AHI< 22.5 h-1 AHI ≥ 22.5 h-1 P-value 
n   97 176  
Age (years)  59 ± 11 65 ± 9 0.028 
Female (%)  16  11 < 0.001 
BMI (kg/m2)  27.9 ± 4.4  30.3 ± 5.6  0.002 
LVEF (%)a  30 (25; 38)  34 (25; 44)  0.349 
NYHA class  
 
2.2 ± 0.5  2.4 ± 0.5  < 0.001 
Ischaemic cardiomyopathy (%)  39  59  0.569 
Atrial fibrillation (%)  21  25  0.322 
Cardiovascular risk factors    
 Hypertension (%)  45  57  0.645 
 Diabetes (%)  26  39  < 0.001 
 Hyperlipidaemia (%)  57  66  0.011 
Rhythm devices    
 Pacemaker (%)  19  30  < 0.001 
 Biventricular pacemaker (%)  8  5  0.042 
 Defibrillator (%)  26  27  0.59 
Medications    
 ACE-inhibitors/ 
  AT1-antagonists (%) 
94  93  0.688 
 Diuretics (%)  88  90  0.169 
 ß-blockers (%)  91  88  0.105 
 Spironolactone (%)  62  49  0.001 
 Digitalis (%)  29  25  0.178 
 Lipid lowering agents (%)  46  63  0.017 
    
 
a
LVEF is not normally distributed, reported as median (interquartile range), and differences between 
groups were compared with the Mann–Whitney U-test. 
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Table 3 Polysomnographic data of patients 
 
 AHI< 22.5 h-1 AHI ≥ 22.5 h-1 P-value 
AHI (h-1) 12 ± 7  45 ± 17  < 0.001 
Obstructive events (%) 30 ± 34  25 ± 30  0.078 
Mean O2 saturation (%) 93 ± 2  92 ± 3  0.122 
Minimum O2 saturation (%) 85 ± 6  76 ± 10  < 0.001 
Total sleep time (min) 343 ± 49  320 ± 70  0.006 
Sleep latency (min) 36 ± 29  38 ± 28  0.504 
Sleep efficiency (%) 85 ± 10  81 ± 14  0.007 
Arousals (h-1)  21 ± 14  33 ± 19  < 0.001 
Slow and REM sleep (%) 35 ± 4  26 ± 2  0.008 
Nocturnal heart rate (min-1) 61 ± 3  60 ± 2  0.616 
Daytime sleepiness (ESS) 6.5 ± 4.3  7.9 ± 4.4  0.757 
PAP treatment, n (%) 21 (22)  91 (52)  0.001 
 
 
4.1. Impact of sleep disordered breathing on survival 
Sixty CHF patients with severe SDB died (34%), whereas in the group without severe SDB 
17 deaths occurred (18%, P = 0.003; Figure 2). After accounting for significant confounding 
factors (age, NYHA-functional class, cause of CHF, diabetes, and PAP treatment), patients 
with severe SDB had a two-fold increased hazard ratio for death [2.0, 95% confidence 
interval (CI) 1.1–3.5; P = 0.023], indicating significantly higher mortality of patients with 
severe SDB compared with patients without severe SDB. Other variables listed in Table 1 
were not significant confounders and were not included in the final model. 
In the group with severe SDB, 53% of the deaths occurred due to progressive heart failure, 
5% due to stroke, 3% due to sudden cardiac death, and 7% were related to a surgical 
procedure (coronary bypass surgery, mitral valve reconstruction, or carotid 
thrombarterectomy). Of the remaining patients (15%), causes of death were non-
cardiovascular (pneumonia, pancreatitis, and cancer). The causes of 17% of deaths were 
unknown. 
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Figure 2 Kaplan–Meier plots for patients without severe sleep-disordered breathing (SDB, defined as 
apnoea–hypopnoea index < 22.5 h
-1
) and severe sleep-disordered breathing (apnoea–hypopnoea 
index ≥ 22.5 h
-1
). Survival was computed using unadjusted Cox proportional hazard analysis. HR, 
hazard ratio; CI, confidence interval. 
 
 
4.2. Impact of sleep disordered breathing on survival in patients with ischaemic 
and non-ischaemic cardiomyopathy 
In patients with ischaemic (n = 142, 53 deaths) and non-ischaemic cardiomyopathy (n = 131, 
24 deaths), severe SDB was associated with a similarly increased hazard ratio for death (1.8, 
95% CI 0.9 – 3.5, P = 0.107 vs. 2.2, 95% CI 0.9 – 3.5, P = 0.078). 
 
4.3. Impact of obstructive and central sleep apnoea on survival 
In the severe SDB group (n = 176), 22% of patients had predominantly OSA and 78% CSA. 
Comparing the severe and the mild OSA group, mortality was similar (19 vs. 21%, P = 
0.884). In contrast, mortality was significantly higher in the severe CSA group compared with 
the mild CSA group (38 vs. 16%; unadjusted P = 0.002 and adjusted for the significant 
confounders age and NYHA class P = 0.035). 
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4.4. Impact of positive airway pressure support on survival:  
intention-to-treat analysis 
In an intention-to-treat analysis of the severe SDB group, we compared patients who started 
a trial of PAP at home after in-hospital treatment initiation (74%) with patients who did not 
start a trial of PAP at home (26%). Mortality was not significantly different between the 
treated and untreated groups (28 vs. 51%, P = 0.247). With a total of 60 events, this analysis 
had 62% power to detect the above decrease of mortality in favour of the PAP-treated group 
at a two-sided alpha level of 0.05. 
 
4.5. Impact of positive airway pressure support on survival:  
on-treatment analysis 
An on-treatment analysis compared patients with severe SDB who used PAP for at least 6 
months or until death (PAP-treated, 52%) and those who used PAP for less than 6 months 
(untreated, 48%; Table 4). Nine percent of the patients with untreated SDB terminated PAP 
therapy during initiation. Eleven percent of the patients terminated PAP therapy until the next 
clinical visit after 3 months. Baseline characteristics and polysomnographic data are shown 
in Tables 4 and 5. 
Untreated patients had advanced diseases with respect to the underlying cardiovascular 
disease: ischaemic cardiomyopathy, atrial fibrillation, and biventricular pacing were more 
frequent in the untreated compared with the treated group. Patients with untreated SDB were 
significantly more often treated with beta-blockers compared with patients treated with PAP 
therapy (Table 4). In contrast, PAP-treated patients had more severe SDB than untreated 
patients, a higher percentage of obstructive episodes, and were more obese. Forty-eight 
percent of the PAP-treated patients were treated with continuous PAP, 13% with bi-level 
PAP, and 39% with adaptive servoventilation. 
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Table 4 Baseline characteristics of patients with use of positive airway pressure 
therapy vs. untreated sleep disordered breathing 
 
 PAP-treated  
severe SDB 
Untreated  
severe SDB 
P-value 
n  91 85  
Age (years)  65 ± 10  65 ± 9  0.68 
Female (%)  7  6  0.699 
BMI (kg/m2)  30.6 ± 6.2  29.9 ± 4.9  0.006 
LVEF (%)a  35 (28; 45)  30 (25; 36)  < 0.001 
NYHA class  2.3 ± 0.5  2.5 ± 0.5  0.009 
Ischaemic cardiomyopathy (%) 55  64  0.033 
Atrial fibrillation  20  29  0.04 
Cardiovascular risk factors 
 
   
 Hypertension (%)  57  57  0.893 
Diabetes (%)  36  41  0.196 
Hyperlipidaemia (%)  64  68  0.212 
Rhythm devices    
 Biventricular pacemaker (%) 3  7 0.032 
 Defibrillator (%)  25  29  0.223 
Medications 
 
   
 ACE-inhibitors/ 
  AT1-antag. (%) 
94  
 
92  0.343 
 Diuretics (%)  89  92  0.218 
 Spironolactone (%)  55  44  0.843 
 ß-Blocker (%)  85  91  0.016 
 Digoxin (%)  23  27  0.227 
 Lipid lowering agents (%)  64  62  0.707 
 
a
LVEF is not normally distributed, reported as median (interquartile range), and differences between 
groups were compared with the Mann–Whitney U-test. 
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Table 5 Polysomnographic data of patients with use of positive airway pressure 
therapy vs. untreated sleep disordered breathing 
 
 PAP-treated 
severe SDB 
Untreated  
severe SDB 
P-value 
AHI (h-1) 48.9 ± 19  41.9 ±13  0.017 
Obstructive events (%) 31 ±32  18 ±27  0.011 
Mean O2 saturation (%) 92 ±3  92 ±2  0.076 
Minimum O2 saturation (%) 75 ±11  78 ±7  0.001 
Total sleep time (min) 323 ±72  317 ±69  0.791 
Sleep latency (min) 36 ±27  40 ±29  0.793 
Sleep efficiency (%) 81 ±16  80 ±16  0.085 
Arousals (h-1)  38 ±21  29 ±16  0.063 
Slow and REM sleep (%) 26 ±3  25 ±2  0.741 
Nocturnal heart rate (min-1) 60 ±4  59 ±3  0.554 
Daytime sleepiness (ESS) 7.9 ±4.5 7.8 ±4.1  0.591 
 
 
 
Mortality in the PAP-treated group (18%, 16 deaths) was lower than the mortality of patients 
with untreated SDB (52%, 44 deaths, P < 0.001, Figure 3 A). In the PAP-treated group, eight 
deaths occurred due to progressive heart failure, three due to acute myocardial infarction, 
one due to stroke, one due to pneumonia, and one death was temporally related to coronary 
bypass surgery. None of the reported deaths was sudden cardiac death. The causes of 
death remain unknown in two patients. 
Positive airway pressure-treated patients had a significantly decreased hazard ratio for death 
(0.3, 95% CI 0.2–0.6; P < 0.001), indicating significantly better survival in patients undergoing 
PAP treatment. In a multivariate Cox-proportional hazard model accounting for the significant 
confounders age, NYHA class, cause of CHF, and diabetes through a propensity score, 
PAP-treated patients still had a significantly decreased hazard ratio for death (0.4, 95% CI 
0.2–0.6; P = 0.001). Other variables listed in Table 1 were not significant confounders and 
were not included in the final model.  
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In the subgroup of patients with severe CSA, the PAP-treated group showed a lower hazard 
ratio for death compared with the untreated group at any time point of the follow-up period 
(unadjusted HR 0.4, 95% CI 0.2–0.7; P = 0.001; adjusted HR 0.4, 95% CI 0.2–0.7; P =0.004; 
Figure 3 B). 
 
 
Figure 3 (A and B) Kaplan–Meier plots for patients with severe sleep-disordered breathing (SDB, 
apnoea–hypopnoea index ≥ 22.5 h
-1
, A) and the subgroup of patients with severe central sleep 
apnoea (CSA, B) with and without positive airway pressure (PAP, defined as treatment .6 months or 
until a primary event). The unadjusted and adjusted Cox proportional hazard model is shown. The 
adjusted Cox proportional hazard model accounts for the significant confounders age, NYHA-class, 
cause of CHF, and diabetes through a propensity score. HR, hazard ratio; CI, confidence interval. 
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5. Discussion 
This observational study of a large sample of CHF patients on contemporary medical 
therapy, who were evaluated for SDB by in-lab polysomnography, has given rise to several 
important findings: (i) SDB confers an increased risk for death in patients with CHF 
independently of conventional risk factors, (ii) PAP treatment of patients with severe SDB, 
which was initiated with attended polysomnographic monitoring and targeted to suppression 
of SDB, was not associated with an increased mortality rate at any time point of the follow-up 
period, and (iii) patients with severe SDB who used PAP treatment had a significantly lower 
mortality rate compared with those with untreated SDB. 
In accordance with previously published data, we found that SDB and specifically CSA are a 
risk factor for increased mortality in patients with CHF, independent of known risk factors for 
death in heart failure patients.8,10 – 13 Since in the group with severe SDB, only 7% of the 
deaths were due to sudden cardiac death, our data do not support a link between SDB and 
increased risk for sudden cardiac death.32 The finding in the present analysis that medication 
did not significantly influence the hazard ratio for death according to the SDB category 
suggests that improvements in CHF medication reduced overall mortality, but did not alter 
the impact of SDB and CSA on the outcome among this group of patients. In line with 
previous studies, 7, 33 neither CHF patients in the group without severe SDB nor in the severe 
SDB group reported excessive daytime sleepiness assessed with the ESS (Table 3). 
Our study in CHF patients with polysomnographic assessment of SDB extends the findings 
of previous studies in several important ways: (i) while in previously published studies the 
level of beta-blocker use was either not reported9, 11, 17 or as low as 10 – 53%, 8, 10, 12, 17, 18 in 
our study it was 91 and 88% in the group without severe SDB and the severe SDB group, 
respectively. Beta-blocker use is of crucial importance for outcome studies in CHF patients, 
since the implementation of beta-blockers in medical therapy for CHF has significantly 
improved survival.19, 20 (ii) In contrast to previous studies using portable sleep apnoea 
monitoring devices,8, 11 the use of in-lab polysomnography with quantitative measurements of 
airflow and thoraco-abdominal effort enabled us to distinguish between CSA and OSA. By 
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this means we could attribute the association of SDB and poor prognosis in CHF patients in 
the reported sample to CSA. (iii) Our observational study included a significant proportion of 
patients in whom PAP therapy was initiated. 
While treatment effects can hardly be proved by observational studies, this study type can 
add important information with respect to the safety of a treatment. The concern that PAP 
therapy may be harmful in some CHF patients with CSA, which was raised by the results of 
the CANPAP trial showing an increased event rate in the CPAP-treated compared with the 
control group in the first 18 months after treatment initiation,22 is not supported by our 
observational data (Figure 3 B). One potential reason for this is that at our centre, PAP 
treatment in CHF patients with SDB was always initiated in hospital under polysomnographic 
monitoring, which was not mandatory in the CANPAP trial.22 
The present study is subject to several limitations. First, due to the fact that the majority of 
CHF patients referred for full in-laboratory polysomnography in our study had suspected 
SDB, our study is limited by a shortage of patients without SDB to serve as a control group. 
We therefore compared patients with severe SDB vs. patients with absent-to-moderate SDB 
(group without severe SDB). This may have caused a conservative bias which would tend to 
underestimate the true mortality risk of severe SDB rather than identifying a false positive 
mortality risk. Secondly, although we studied a larger sample compared with previously 
published outcome studies of CHF patients with the assessment of SDB, our study ultimately 
lacked the statistical power to draw firm conclusions about the impact of OSA on mortality in 
such patients. Thirdly, in observational studies, differences in mortality rates between 
patients who adhere to PAP therapy and those who do not use PAP therapy cannot 
imperatively be attributed to treatment effects: e.g. the adherence to PAP therapy may be 
paralleled by adherence to heart failure medication. Enhanced adherence to medical therapy 
for heart failure is known to be associated with improved survival.34 
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6. Conclusions 
We conclude that CHF patients on contemporary medical therapy with severe SDB have a 
significantly higher mortality risk than patients with absent or less severe SDB. Our data 
show that SDB contributes to progression of CHF and mortality, independent of established 
risk factors. Patients with CHF and severe SDB (CSA and OSA) who adhered to PAP 
treatment had a good prognosis, and PAP treatment was not associated with increased 
mortality at any time point during the follow-up period. In view of the multiple associations of 
SDB to known risk factors for death and worsening of CHF, randomized treatment trials with 
PAP are warranted to establish a causal relationship between SDB and worsening of CHF 
and to assess the effects of PAP treatment as a non-pharmacological adjunct to heart failure 
therapy on long-term morbidity and mortality in such patients. 
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Prognostischer Einfluss von schlafbezogenen Atemstörungen und deren Behandlung 
bei Herzinsuffizienz: eine Beobachtungsstudie 
Schlaf bezogene Atemstörungen (SDB) können zum Progress der Erkrankung bei Patienten 
mit chronischer Herzinsuffizienz beitragen. Der Ansatz dieser Beobachtungsstudie besteht 
darin zu evaluierten, ob schlafbezogenen Atemstörungen ein Risikofaktor für Mortalität bei 
Patienten mit chronischer Herzinsuffizienz ist und ob dieser Risikofaktor durch eine 
Behandlung über Applikation eines positiven Atemwegsdruck (PAP) gesenkt werden kann. 
Wir untersuchten 296 Patienten mit chronischer Herzinsuffizienz (mittlere linksventrikuläre 
Ejektionsfraktion 33%) retrospektiv von Januar 2002 bis Dezember 2009. Bei all diesen 
Patienten war in einem Schlaflabor eine Polysomnographie durchgeführt worden. Im 
Anschluss verglichen wir zum einen die Mortalität zwischen Patienten mit einer 
schwerwiegenden schlafbezogenen Atemstörung [Apnoe-Hypopnoe-Index (AHI) ≥ 22,5 h-1] 
mit solchen ohne schwerwiegende SDB (AHI < 22,5 h-1). Desweiteren bewerteten wir den 
Einfluss der Behandlung mit PAP auf die Mortalität bei Patienten mit schwerwiegender SDB. 
Nach der Berechnung der signifikanten Einflussgrößen (Alter, NYHA-Klasse, Ursache der 
Herzinsuffizienz, Diabetes mellitus und Behandlung mit PAP) zeigte sich, dass Patienten mit 
II 
 
schwerer SDB (n = 176) verglichen mit Patienten ohne schwerwiegende SDB eine 2,0-fach 
höhere Hazard-Ratio hinsichtlich eines letalen Verlaufes hatten [95% Confidenz-Intervall (CI) 
1,1 – 3,5; p = 0,023). In einer adjustierten On-Treatment-Analyse derjenigen Patienten mit 
schwerwiegender SDB zeigte sich eine signifikant niedrigere Mortalitätsrate bei mit PAP-
behandelten Patienten (18%), verglichen mit denjenigen, welche als unbehandelt eingestuft 
wurden (52%; Hazard-Ratio 0,4; 95% CI 0,2 – 0,6; p = 0,001). Insgesamt war die Mortalität in 
der mit PAP-therapierten Gruppe verglichen mit der unbehandelten Gruppe zu jedem 
Zeitpunkt im gesamten Follow-up niedriger. 
Das Vorliegen einer schwerwiegenden SDB stellt somit unabhängig von bereits etablierten 
Risikofaktoren ein signifikant erhöhtes Mortalitätsrisiko bei Patienten mit chronischer 
Herzinsuffizienz dar. Bei chronisch herzinsuffizienten Patienten mit schlafbezogenen 
Atemstörungen war die Anwendung von PAP-Therapie assoziiert mit einer reduzierten 
Mortalitätsrate zu jedem Zeitpunkt des Follow-up, was nahelegt, dass die PAP-Therapie 
gefahrlos bei eben diesen Patienten eingesetzt werden kann. 
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Abkürzungsverzeichnis:  
ACE Angiotensin-converting enzyme 
AHI Apnoea-hypopnoea index 
BMI Body mass index 
CHF Chronic heart failure 
CI Confidence interval 
CANPAP Canadian continuous positive airway pressure for patients 
with central sleep apnoea and heart failure trial 
Cox-PH Cox proportional hazard  
CPAP Continuous positive airway pressure  
CSA Central sleep apnoea 
ESS Epworth Sleepiness Scale 
HR Hazard ratio 
HTX Heart transplantation 
LVEF Left ventricular ejection fraction 
NYHA New York heart association 
OSA Obstructive sleep apnoea 
PAP Positive airway pressure 
REM Rapid eye movement 
ROC Receiver operating characteristics 
SaO2 Arterial oxy-haemoglobin saturation 
SDB Sleep disordered breathing 
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Abbildungsverzeichnis: 
 
Figure 1 Progress of the cohort through the study. CHF, chronic heart failure; PSG, polysomnography; 
mo, months; LVEF, left ventricular ejection fraction; no severe SDB, sleep-disordered breathing 
defined as apnoea–hypopnoea index < 22.5 h
-1
; severe SDB, severe sleep disordered breathing 
defined as apnoea–hypopnoea index ≥ 22.5 h
-1
. 
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Figure 2 Kaplan–Meier plots for patients without severe sleep-disordered breathing (SDB, defined as 
apnoea–hypopnoea index < 22.5 h
-1
) and severe sleep-disordered breathing (apnoea–hypopnoea 
index ≥ 22.5 h
-1
). Survival was computed using unadjusted Cox proportional hazard analysis. HR, 
hazard ratio; CI, confidence interval. 
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Figure 3 (A and B) Kaplan–Meier plots for patients with severe sleep-disordered breathing (SDB, 
apnoea–hypopnoea index ≥ 22.5 h
-1
, A) and the subgroup of patients with severe central sleep 
apnoea (CSA, B) with and without positive airway pressure (PAP, defined as treatment .6 months or 
until a primary event). The unadjusted and adjusted Cox proportional hazard model is shown. The 
adjusted Cox proportional hazard model accounts for the significant confounders age, NYHA-class, 
cause of CHF, and diabetes through a propensity score. HR, hazard ratio; CI, confidence interval. 
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Tabellenverzeichnis: 
Table 1 Possible confounders for death 
 
Age, gender, body-mass index (BMI) 
LVEF, NYHA class, cause of CHF (ischaemic/non-ischaemic), Atrial fibrillation  
History of hypertension, diabetes, and hyperlipidaemia 
Biventricular pacemaker, defibrillator 
ACE-inhibitors/AT1-receptor antagonists, spironolactone, ß-receptor-blockers,  
digitalis, diuretics, lipid reducers 
Positive airway pressure treatment 
 
Significant confounders (> 10% change in hazard ratio for death according to category of sleep-
disordered breathing) are marked in bold. 
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Table 2 Baseline characteristics of patients without severe sleep disordered breathing 
(AHI < 22.5 h-1) and severe sleep disordered breathing (AHI ≥ 22.5 h-1) 
 AHI< 22.5 h-1 AHI ≥ 22.5 h-1 P-value 
n   97 176  
Age (years)  59 ± 11 65 ± 9 0.028 
Female (%)  16  11 < 0.001 
BMI (kg/m2)  27.9 ± 4.4  30.3 ± 5.6  0.002 
LVEF (%)a  30 (25; 38)  34 (25; 44)  0.349 
NYHA class  
 
2.2 ± 0.5  2.4 ± 0.5  < 0.001 
Ischaemic cardiomyopathy (%)  39  59  0.569 
Atrial fibrillation (%)  21  25  0.322 
Cardiovascular risk factors    
 Hypertension (%)  45  57  0.645 
 Diabetes (%)  26  39  < 0.001 
 Hyperlipidaemia (%)  57  66  0.011 
Rhythm devices    
 Pacemaker (%)  19  30  < 0.001 
 Biventricular pacemaker (%)  8  5  0.042 
 Defibrillator (%)  26  27  0.59 
Medications    
 ACE-inhibitors/ 
  AT1-antagonists (%) 
94  93  0.688 
 Diuretics (%)  88  90  0.169 
 ß-blockers (%)  91  88  0.105 
 Spironolactone (%)  62  49  0.001 
 Digitalis (%)  29  25  0.178 
 Lipid lowering agents (%)  46  63  0.017 
    
 
a
LVEF is not normally distributed, reported as median (interquartile range), and differences between 
groups were compared with the Mann–Whitney U-test. 
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Table 3 Polysomnographic data of patients 
 
 AHI< 22.5 h-1 AHI ≥ 22.5 h-1 P-value 
AHI (h-1) 12 ± 7  45 ± 17  < 0.001 
Obstructive events (%) 30 ± 34  25 ± 30  0.078 
Mean O2 saturation (%) 93 ± 2  92 ± 3  0.122 
Minimum O2 saturation (%) 85 ± 6  76 ± 10  < 0.001 
Total sleep time (min) 343 ± 49  320 ± 70  0.006 
Sleep latency (min) 36 ± 29  38 ± 28  0.504 
Sleep efficiency (%) 85 ± 10  81 ± 14  0.007 
Arousals (h-1)  21 ± 14  33 ± 19  < 0.001 
Slow and REM sleep (%) 35 ± 4  26 ± 2  0.008 
Nocturnal heart rate (min-1) 61 ± 3  60 ± 2  0.616 
Daytime sleepiness (ESS) 6.5 ± 4.3  7.9 ± 4.4  0.757 
PAP treatment, n (%) 21 (22)  91 (52)  0.001 
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Table 4 Baseline characteristics of patients with use of positive airway pressure 
therapy vs. untreated sleep disordered breathing 
 
 PAP-treated  
severe SDB 
Untreated  
severe SDB 
P-value 
n  91 85  
Age (years)  65 ± 10  65 ± 9  0.68 
Female (%)  7  6  0.699 
BMI (kg/m2)  30.6 ± 6.2  29.9 ± 4.9  0.006 
LVEF (%)a  35 (28; 45)  30 (25; 36)  < 0.001 
NYHA class  2.3 ± 0.5  2.5 ± 0.5  0.009 
Ischaemic cardiomyopathy (%) 55  64  0.033 
Atrial fibrillation  20  29  0.04 
Cardiovascular risk factors 
 
   
 Hypertension (%)  57  57  0.893 
Diabetes (%)  36  41  0.196 
Hyperlipidaemia (%)  64  68  0.212 
Rhythm devices    
 Biventricular pacemaker (%) 3  7 0.032 
 Defibrillator (%)  25  29  0.223 
Medications 
 
   
 ACE-inhibitors/ 
  AT1-antag. (%) 
94  
 
92  0.343 
 Diuretics (%)  89  92  0.218 
 Spironolactone (%)  55  44  0.843 
 ß-Blocker (%)  85  91  0.016 
 Digoxin (%)  23  27  0.227 
 Lipid lowering agents (%)  64  62  0.707 
 
a
LVEF is not normally distributed, reported as median (interquartile range), and differences between 
groups were compared with the Mann–Whitney U-test. 
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Table 5 Polysomnographic data of patients with use of positive airway pressure 
therapy vs. untreated sleep disordered breathing 
 
 PAP-treated 
severe SDB 
Untreated  
severe SDB 
P-value 
AHI (h-1) 48.9 ± 19  41.9 ±13  0.017 
Obstructive events (%) 31 ±32  18 ±27  0.011 
Mean O2 saturation (%) 92 ±3  92 ±2  0.076 
Minimum O2 saturation (%) 75 ±11  78 ±7  0.001 
Total sleep time (min) 323 ±72  317 ±69  0.791 
Sleep latency (min) 36 ±27  40 ±29  0.793 
Sleep efficiency (%) 81 ±16  80 ±16  0.085 
Arousals (h-1)  38 ±21  29 ±16  0.063 
Slow and REM sleep (%) 26 ±3  25 ±2  0.741 
Nocturnal heart rate (min-1) 60 ±4  59 ±3  0.554 
Daytime sleepiness (ESS) 7.9 ±4.5 7.8 ±4.1  0.591 
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